SOLTF

Sosei Group Corporation

SOLTF, USA

Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist in phase 2 trial for narcolepsy and preclinical trial for EDS in neurology. Its products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; PF-06954522, a GLP-1 agonist for metabolic diseases; and NBI-1117570, a dual muscarinic M1/M4 agonist, NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; NXE0048149, a GPR52 agonist for schizophrenia; and NXE0039732, an EP4 antagonist for immuno-oncology. The company's products in preclinical trial comprise NBI-1117567, a muscarinic M1-preferring agonist for neurology; KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. It also develops other discovery-stage drugs. The company has strategic collaborations with Verily, PeptiDream, Tempero Bio, Pharmenable Therapeutics, Kallyope, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Boehringer Ingelheim, Lilly, AbbVie, Biohaven pharmaceuticals, Takeda, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and PrecisionLife. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato-ku, Japan.

https://www.nxera.life

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SOLTF
stock
SOLTF

ManpowerGroup Stock: Holding Pattern In A Soft Labor Market (NYSE:MAN) Seeking Alpha

Read more →
SOLTF
stock
SOLTF

Stock futures jump after soft November inflation data, Nasdaq futures lead on Micron boost (SPX:) Seeking Alpha

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.16

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-2.55 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-1.16 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-45.57 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.20

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Sosei Group Corporation

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

73.9

Latest Release

Date

2025-09-30

EPS Actual

-0.1253

EPS Estimate

22.29

EPS Difference

-22.4153

Surprise Percent

-100.5621%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.